About Us

Human Immunology Project Consortium (HIPC)

The Human Immunology Project Consortium (HIPC) program was established in 2010 by the NIAID Division of Allergy, Immunology, and Transplantation as part of the overall NIAID focus on human immunology. Through this program, well-characterized human cohorts are studied using a variety of modern analytic tools, including multiplex transcriptional, cytokine, and proteomic assays; multiparameter phenotyping of leukocyte subsets; assessment of leukocyte functional status; and multiple computational methods.

Through the HIPC program, centralized research resources and a comprehensive, centralized database will be constructed for use by the greater scientific community. The information gained from the HIPC program will provide a comprehensive understanding of the human immune system and its regulation, and will reveal novel associations between components of the immune system and other biological systems, identify novel immune mediators and pathways, establish predictors of vaccine safety in different populations, and enable the rapid evaluation of different vaccine formulations and administration regimens in human populations. This knowledge base will also serve as a foundation for the future study of immune-mediated diseases in the human, such as allergy, asthma, transplant rejection, and autoimmune diseases, and a variety of inflammatory diseases.

HIPC MISSION

GOALS:

  • Define profiles/signatures/fingerprints of steady-state and activated human immune system
  • Create centralized knowledge base & resources
    • facilitate investigations of human immunity
    • develop novel applications for human disease

STUDY:

  • Perturbations of the steady-state by infection
  • Vaccination
  • Adjuvant administration

METHODS:

  • Define human transcriptome/proteome using bioinformatics
  • Multiplex assays
  • Multiparameter phenotyping, systems biology
  • Mass spectrometry

HIPC STEERING COMMITTEE

The Steering Committee (SC) is comprised of the principal investigators from each HIPC center as well as DHHS scientists and staff. The SC serves as the governing board of the network and directs the collaborative work of the HIPC investigators, determines the use of the Infrastructure and Opportunities Fund, evaluates the progress and direction of the individual awardees and network, and makes recommendations for the continuation or re-direction of projects on an ongoing basis and in consultation with NIAID. The SC Chair is elected annually by majority vote from among the non-Government SC members.

  • Chair: Ellis Reinherz- Dana-Farber Cancer Institute
  • Mark Davis- Stanford University
  • Ronald Germain- NIH/NIAID
  • Hana Golding- FDA/CBER
  • David Hafler- Yale University
  • M. Virginia Pascual- Baylor Research Institute
  • Gregory Poland- Mayo Clinic
  • Bali Pulendran- Emory University
  • Helen Quill- NIH/NIAID
  • Kenneth Stuart- Seattle Biomedical Research Institute
  • Alkis Togias- NIH/NIAID

HIPC SCIENTIFIC ADVISORY BOARD

The Scientific Advisory Board (SAB) was established in 2011 to provide advice to NIAID on the progress of scientific studies, to identify gaps within the program, and to review and recommend new opportunities that will contribute to fulfillment of the HIPC mission. SAB members attend the semi-annual investigator meetings to review and discuss HIPC progress and deliverables with the HIPC Steering Committee and with NIAID management staff.

  • Peter Ghazal- University of Edinburgh
  • Barney Graham- NIH/NIAID
  • Adrian Hayday- King's College London
  • Richard Koup- NIH/NIAID
  • Jonathan McCullers- St. Jude Hospital
  • Dennis Metzger- Albany Medical College
  • Eleanor Riley- London School of Hygiene and Tropical Medicine
  • Joachim Schultze- University of Bonn
  • John Treanor- University of Rochester